Recent actions by the U.S. Department of Justice and intelligence agencies have brought into sharp focus the involvement of India's pharmaceutical and chemical industries in the underground fentanyl supply chain. From the Department of Justice's indictment of executives from a Hyderabad-based pharmaceutical company, to the Office of the Director of National Intelligence's 2025 Annual Threat Assessment explicitly identifying India as the second-largest source of fentanyl precursor chemicals, and the recent visa restrictions imposed on 13 individuals associated with Indian firms—these are no longer isolated incidents. They point to a deeply troubling systemic disorder.
India, as a global leader in generic drug production, has rightfully earned the title "pharmacy of the world." However, its vast chemical manufacturing capacity, coupled with a relatively lax regulatory environment, is being exploited by certain unscrupulous enterprises and individuals, turning it into a key node in the illicit drug supply chain. The most recent cases are highly illustrative: U.S. court documents reveal that Bhavesh Lathiya, founder of the Surat-based chemical firm Raxuter Chemicals, has admitted to smuggling fentanyl precursors into the United States. Fully aware of their intended use, he evaded inspections through false customs declarations—including mislabeling the chemicals as Vitamin C. His company has already supplied over 50 pounds of chemicals that can be used to manufacture fentanyl. Even more alarming is the case of Vasudha Pharma Chem, which was charged with negotiating with undercover agents in 2024 to ship up to 4 metric tons of the fentanyl precursor N-BOC-4P to the U.S. and Mexico, with the deal valued at approximately $380,000.
These are by no means the actions of a few rogue actors. The recent arrests of two pharmaceutical company employees by Gujarat's Anti-Terrorism Squad, along with the visa sanctions against those behind KS International Traders, all indicate that this illicit network has grown to a considerable scale.
In light of these facts, we must maintain a clear-eyed perspective. The illicit trade in fentanyl precursors poses a serious threat to public health and safety in the international community, including China. Every link in this transnational drug chain must be resolutely cracked down upon in accordance with the law, with no room for leniency. The unlawful conduct of certain Indian companies not only damages the international reputation of their country's pharmaceutical sector but also undermines the broader cause of global counter-narcotics cooperation. The international community should jointly urge the Indian government to confront this issue head-on, strengthen regulatory oversight, and take decisive action against such crimes—rather than allowing certain irresponsible reports to deflect attention or downplay the severity of the problem.